Physician profile
Anthony Ricco
NPI 1568817435
$3,621.08
in general payments reported to CMS, 2019-2025
37 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.99 · 2021: $382 · 2022: $676 · 2023: $285 · 2024: $814 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $753.34 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $373.81 | 2021-2025 | Erleada, Rybrevant, Talvey |
| Novartis Pharmaceuticals Corporation | $259.85 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $157.65 | 2024 | Varian Ethos Treatment Planning |
| Daiichi Sankyo INC. | $156.95 | 2024-2025 | Enhertu, Datroway |
| Galvanize Therapeutics, INC | $152.02 | 2022 | |
| Novocure INC. | $137.93 | 2022-2024 | Optune |
| Myovant Sciences INC. | $137.13 | 2021-2022 | |
| Boston Scientific Corporation | $133.75 | 2020-2024 | Spaceoar System |
| Regeneron Healthcare Solutions, INC. | $121.56 | 2024-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $89.15 | 2023-2025 | Orgovyx |
| Incyte Corporation | $88.43 | 2025 | Zynyz, Monjuvi, Niktimvo |
| Genentech USA, INC. | $64.46 | 2024-2025 | Venclexta |
| Astellas Pharma US INC | $63.61 | 2023-2025 | Xtandi, Vyloy |
| Caris Mpi, INC. | $62.65 | 2025 | Mi Cancer Seek |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $62.02 | 2022 | |
| Karyopharm Therapeutics INC. | $59.87 | 2024-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $59.26 | 2025 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $54.92 | 2022-2023 | Myrisk |
| Brainlab, INC. | $54.01 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Eisai INC. | $52.94 | 2024-2025 | |
| Genmab U.S., INC. | $49.66 | 2024-2025 | Epkinly, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $49.32 | 2024-2025 | Ninlaro, Alunbrig |
| Abbvie INC. | $49.29 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.87 | 2024-2025 | |
| Lilly USA, LLC | $42.92 | 2024-2025 | Verzenio, Zepbound |
| Telix Pharmaceuticals | $40.46 | 2023-2024 | Illuccix |
| Sobi, INC | $39.10 | 2025 | |
| Acrotech Biopharma INC. | $29.40 | 2025 | Beleodaq |
| Blue Earth Diagnostics | $27.18 | 2021 | |
| Recordati_rare_diseases_inc. | $23.87 | 2025 | Sylvant |
| Genzyme Corporation | $22.35 | 2022 | |
| Stemline Therapeutics INC. | $22.34 | 2024 | Orserdu |
| Syndax Pharmaceuticals, INC. | $22.11 | 2025 | Revuforj |
| Puma Biotechnology, INC. | $21.73 | 2024 | |
| Tersera Therapeutics LLC | $19.48 | 2025 | Zoladex |
| Progenics Pharmaceuticals, INC. | $18.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ricco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.